BIOTALYS NV |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.04 EUR | +1.33% |
|
-2.56% | -34.90% |
| Mar. 18 | Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development | MT |
| Mar. 18 | Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 219.3 | 210.5 | 149.9 | 96.47 | - |
| Enterprise Value (EV) 1 | 170.5 | 180.8 | 149.9 | 96.47 | 96.47 |
| P/E ratio | -6.47 x | -9.19 x | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 110 x | 71.4 x | 57.4 x | 32.2 x | 32.2 x |
| EV / Revenue | 110 x | 71.4 x | 57.4 x | 32.2 x | 32.2 x |
| EV / EBITDA | -13.2 x | -10 x | - | -11.2 x | -11 x |
| EV / FCF | -12,132,729 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | - | 5.52 x | - | - | - |
| Nbr of stocks (in thousands) | 30,806 | 30,949 | 32,095 | 32,157 | - |
| Reference price 2 | 7.120 | 6.800 | 4.670 | 3.000 | 3.000 |
| Announcement Date | 3/11/22 | 2/28/23 | 2/22/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 9.838 | 1.995 | 2.949 | 2.611 | 3 | 3 |
| EBITDA 1 | - | -16.61 | -20.96 | - | -8.6 | -8.8 |
| EBIT | - | -18.08 | -22.53 | - | - | - |
| Operating Margin | - | -906.22% | -764.02% | - | - | - |
| Earnings before Tax (EBT) | - | -16.91 | -22.77 | - | - | - |
| Net income | -13.2 | -16.93 | -22.73 | - | - | - |
| Net margin | -134.17% | -848.57% | -770.8% | - | - | - |
| EPS | - | -1.100 | -0.7400 | - | - | - |
| Free Cash Flow | - | -18.08 | - | - | - | - |
| FCF margin | - | -906.17% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/19/21 | 3/11/22 | 2/28/23 | 2/22/24 | - | - |
1EUR in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | -10.66 |
| Net margin | - |
| EPS 2 | -0.3400 |
| Dividend per Share | - |
| Announcement Date | 8/23/23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 48.9 | 29.7 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -18.1 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -40% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - |
| Book Value Per Share | - | - | 1.230 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 1.32 | - | - | - | - |
| Capex / Sales | - | 66.37% | - | - | - | - |
| Announcement Date | 4/19/21 | 3/11/22 | 2/28/23 | 2/22/24 | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3
EUR
Average target price
6
EUR
Spread / Average Target
+100.00%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.90% | 103M | |
| +0.90% | 7.34B | |
| +7.85% | 3.17B | |
| +11.82% | 843M | |
| -3.44% | 357M | |
| +14.12% | 296M |
- Stock Market
- Equities
- BTLS Stock
- Financials Biotalys NV
